Innovation and the Sustainable Development Goals

Nations Sign First Agreement to Unlock Potential of Emerging Tech

Speaking at a panel organized by the World Economic Forum and the Organisation for Economic Co-operation and Development (OECD), ministers from Canada, Denmark, Italy, Japan, Singapore, United Arab Emirates and United Kingdom announced their plan to lead the world in fostering responsible innovation and entrepreneurship. The Agile Nations Charter sets out each country’s commitment to creating a regulatory environment in which new ideas can thrive. Read full article here.

View Post

Recent Trends in the WHO’s Essential Medicines List

While the number of patented medicines on the EML has increased in recent editions, the portion of the list currently under patent remains a small portion of all drugs on the EML, currently about 10%. A deeper dive into the data shows that many drugs are only patented in a fraction of lower income countries. Thus, 80% of lower income countries have 50 or fewer active patent filings on that ten percent. Moreover, many of these patented drugs are subject to institutionalized programs to provide access at lower cost. This paper provides an update to previous efforts to understand the nature of the EML, while expanding previous information thanks in part to the existence of new freely accessible online databases showing patent status and participation in programs to provide access.

View Post

E-commerce Story Pitch Contest

In this online pitch competition, three e-commerce companies from developing and least developed countries will pitch their story and will be asked a series of questions, with online participants deciding who wins.

In their pitch, finalists will have to provide practical e-commerce insights, actionable tips and innovative approaches. The aim is to share specific learnings, get inspired, and learn useful tips and tools to boost online sales. The winning e-commerce entrepreneur will receive a prize package worth 1,000 USD for digital marketing services.

The three companies are MYANiture from Myanmar, Booksie from Ghana, and Nanjala from Kenya.

View Post

Collaboration to enhance availability of COVID-19 therapeutics

As of November 2020, at least 44 manufacturing and production deals for COVID-19 therapeutics around the globe were made public. A number of these deals were intended to expand access to therapeutics to low and middle-income countries. In relation to all of them, licensing, enabled by a well well-functioning intellectual property system, has been a key enabler.

  • Eli Lilly and Company and the Bill & Melinda Gates Foundation, as part of the COVID-19 Therapeutics Accelerator, have entered into an agreement to facilitate access to future Lilly therapeutic antibodies under development for the prevention and treatment of COVID-19, to benefit low- and middle-income countries. Lilly’s collaborators have agreed to waive their royalties on the Lilly therapeutic antibodies distributed in low- and middle-income countries as part of this initiative.
  • Gilead has entered into voluntary licensing agreements with nine generics manufacturers to further expand supply of remdesivir to 127 countries that represent nearly all low-income and lower-middle income countries. Gilead has completed technology transfers with these companies, and they are beginning the manufacturing process.
  • Merck, IAVI, and Serum Institute of India are collaborating to develop a neutralizing monoclonal antibody treatment for COVID-19. If successful, Merck will lead commercialization in developed countries and the Serum Institute will lead global manufacturing as well as commercialization in low- and middle-low-income countries, including India.
View Post

Collaborations to accelerate COVID-19 vaccine development and distribution

The need for the rapid development and global distribution of a vaccine to prevent COVID-19 infection has spurred a number of novel collaborations between the pharmaceutical companies, research entities, and other stakeholders. These collaborations aim to ensure broad access to new health technologies to address the pandemic.

  • One example is the University of Oxford Jenner Institute vaccine candidate, developed with AstraZeneca, that included collaborations with Catalent Biologics (Italy), Symbiosis Pharmaceutical Services (UK), Oxford Biomedica (UK), Emergent BioSolutionsBioKangtai (China), and R-Pharm (Russia). Through the WHO’s Access to COVID-19 Tools Accelerator, AstraZeneca signed an agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) and Gavi, the Vaccine Alliance, on vaccine development, manufacturing, and procurement, ensuring 300 million doses of the vaccine for low- and middle-income countries. Separately, AstraZeneca also signed a license agreement with the Serum Institute of India (SII) to supply 1 billion doses of vaccine to low- and middle-income countries.
  • Another example involves Sanofi and GSK, which signed a Statement of Intent with Gavi, to make available 200 million doses of their adjuvanted recombinant protein-based COVID-19 vaccine, if approved by regulatory authorities.
  • A third example focuses on Johnson & Johnson.  The company has committed to bringing an affordable vaccine to the public on a not-for-profit basis for emergency pandemic use and anticipates the first batches of a COVID-19 vaccine to be available for emergency use authorization in early 2021.
View Post

How the Oxford COVID vaccine was made so quickly

This article examines the context in which the Oxford COVID vaccine was developed – such as the slow response to the Ebola outbreak – and new technological breakthroughs at Oxford’s Jenner Institute that enabled researchers to cut 10 years of vaccine work down to 10 months.

View Post

Video: World’s first Group B strep vaccine

This video describes how Biovac, in collaboration with PATH and the Bill & Melinda Gates Foundation, is developing the world’s first Group B Strep vaccine.

View Post

SalivaDirect™ COVID-19 test

SalivaDirect™ is a new process developed at the Yale School of Public Health to test persons suspected of having COVID-19 for the virus, SARS-CoV-2. It is ideal for large-scale testing and offers a number of advantages over traditional testing methods.

View Post

Analysis of patent prosecution in China

This paper by Gaetan de Rassenfosse looks for traces of discrimination against foreigners in the patent prosecution process, building on earlier work. It focuses on the case of China, looking in particular at patent applications declared as essential to a technological standard, so called standard-essential patents (SEPs). It finds there is discrimination in the treatment of such patent applications, which are less likely to be granted and/or to take longer to grant.

View Post